Ask AI
ARIA Training Module

CE / CME

Spot the Signal: Global Radiology Training for ARIA Detection in Alzheimer’s Care

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

European Learners: 1.00 EBAC® CE Credit

Released: April 16, 2026

Expiration: April 15, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Hampel H, Elhage A, Cho M, et al. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414-4424.
  2. Lecanemab [prescribing information]. Nutley, NJ: Eisai, Inc.; 2026.
  3. Donanemab [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2024.
  4. Lecanemab [SmPC]. Frankfurt am Main, Germany: Eisai GmbH; 2025.
  5. Donanemab [SmPC]. Fegersheim, France: Lilly France; 2025
  6. Rafii MS, on behalf of the ALZ-NET Study Team. Longitudinal assessment of clinical and safety outcomes in participants receiving beta-amyloid targeting monoclonal antibodies: Real world therapy data from ALZ-NET. Clinical Trials on Alzheimer’s Disease. 2025. Symposium 3.
  7. Rabinovici GM, Selkoe DJ, Schindler SE, et al. Donanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2025;12:100150.
  8. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10:362-377.
  9. Cogswell PM, Andrews TJ, Barakos JA, et al. Alzheimer disease anti-amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol. 2025;46:24-32.
  10. Wiest R, Radojewski P, Liebe JM, et al. Clinical practice recommendations of the Swiss Society for Neuroradiology: neuroimaging standards for enrollment and disease monitoring in anti-amyloid immunotherapies. Neurodegener Dis. 2025;1-12.
  11. American Society of Neuroradiology. ASNR’s Alzheimer’s disease and ARIA study group resources. asnr.org/education-resources/alzheimers-webinar-series/. Accessed March 17, 2026.
  12. Atri A, Dickerson BC, Clevenger C, et al. The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Validated clinical assessment instruments. Alzheimers Dement. 2025;21:e14335.
  13. Winkler DT, Bondolfi L, Herzig MC, et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci. 2001;21:1619-27.
  14. Icometrox. Amyloid-related imaging abnormalities. icometrix.com/amyloid-related-imaging-abnormalities. Accessed March 17, 2026.
  15. Cortech.ai. Neuroquant. Brain segmentation and volumetric analysis for patients with neurodegenerative diseases. cortechs.ai/neuroquant/. Accessed March 17, 2026.
  16. Sima DM, Phan TV, Van Eyndhoven S, et al. Artificial intelligence assistive software tool for automated detection and quantification of amyloid-related imaging abnormalities. JAMA Netw Open. 2024;7: e2355800.
  17. Petrella JR, Liu AJ, Wang LA, et al. AI-assisted detection of amyloid-related imaging abnormalities (ARIA): promise and pitfalls. AJNR Am J Neuroradiol. 2026;47:289-292.
  18. Christodoulou RC, Papageorgiou PS, Sarquis MD, et al. From lesion to decision: AI for ARIA detection and predictive imaging in Alzheimer’s Disease. Biomedicines. 2025;13:2739.